Our unique analytics are driving the next wave of precision medicine insights – finding new treatment opportunities for patients’ unmet medical needs in metabolic, inflammatory, respiratory, cardiovascular, women’s health, neurodegenerative and neuropsychiatric diseases
About usBetter understanding of complex disease biology
We believe that deciphering the complex combinatorial influences on disease biology in patient sub-groups is at the heart of successful drug programs
High-resolution stratification of populations and people
Accurately defining sub-groups of patients enables us to understand their disease risks and drivers, select the right patients for trials, and the right treatment for a patient
New disease insights through collaboration
We bring together data partners, charities, healthcare and life science companies, and Key Opinion Leaders to advance chronic disease outcomes
Why PrecisionLife?
Our unique combinatorial analytics platform unpicks the complex causes of disease and delivers a high-resolution patient stratification based on deep insights into novel target biology.
We bring together data, technology, industry experts and collaborative partners to transform our understanding of chronic disease and find new therapy options for patients.
PrecisionLife’s platform provides detailed contextual information on the SNPs, genes and pathways driving disease in patient sub-groups, and their active chemistry, tissue expression, mechanism of action, IP, clinical trials and more.
Pharma & Biotech
Selecting the right disease biology and drug target is crucial to innovative drug discovery
Clinical Development
Recruiting the right patients is critical to demonstrating efficacy and running smaller, faster and more successful clinical trials
Healthcare
Understanding the personal factors influencing chronic disease risk, progression rate and treatment response is vital to improved care
Latest Disease Studies
Read all Disease StudiesLatest News & Media
View all
News
Publications
Events
From Pepsi to PrecisionLife
A Q&A with our Executive Chairman Ray Pawlicki reflecting on a senior leadership career that moved from Pepsico, to…
24/06/21Ray Pawlicki, Previously CIO at Biogen and Novartis, Joins PrecisionLife as Executive Chair to Accelerate Strategic Expansion
OXFORD, UK June 24th, 2021 –
24/06/21
PrecisionLife and Cyclica sign strategic partnership combining leading data-driven biology and chemistry platforms to create a rapid innovation engine for drug discovery
OXFORD and TORONTO, May 17th, 2021
17/05/21
Bio Digital 2021
June 10-11 & 14-18, 2021 Accelerating a BIO-Revolution through global partnerships, collaboration, and thought leadership We are joining the…
28/04/21
BioNJ’s 11th Annual BioPartnering Conference
Tuesday, May 18 & Wednesday, May 19, 2021 To discuss our extensive pipeline of drug discovery programs that covery…
28/04/21
Genomics & Precision Medicine, April 27th – PMLS Virtual Series 2021
Among the best investments ever made in a technology has been the ability to sequence, annotate, and make functional…
15/04/21
Combinatorial analytics: An essential tool for the delivery of precision medicine and precision agriculture
An Opinion, published in the new Open Access Journal Artificial Intelligence in the Life Sciences from Elsevier, describes the…
31/05/21
Combinatorial analysis of phenotypic and clinical risk factors associated with hospitalized COVID-19 patients
A study using de-identified clinical claims and labs data for US COVID-19 patients. We replicated previous findings around the…
25/02/21
The COVID-19 PHARMACOME: Rational Selection of Drug Repurposing Candidates from Multimodal Knowledge Harmonization
The SARS-CoV-2 pandemic has challenged researchers at a global scale. The scientific community’s massive response has resulted in a…
26/05/21